H.C. Wainwright reiterates Ultragenyx stock rating on FDA approval

The FDA granted full approval to Ultragenyx's FAYUVI (UX111), the first approved treatment for ultra-rare Sanfilippo syndrome Type A and the company's second gene-therapy approval. Analysts maintained constructive views, with H.C. Wainwright reiterating Buy and a $25 target, while Cantor Fitzgerald and Canaccord set $39 targets. The approval offsets, but does not eliminate, key risks: RARE trades at $14.77 after falling 47% over the past year, remains unprofitable and cash-consuming, and its Phase 3 apazunersen study in Angelman syndrome missed primary and secondary endpoints.

Analysis

RARE’s key rerating question is not approval status but launch conversion: ultra-rare CNS gene therapies face concentrated diagnosis, referral, payer prior authorization, and treatment-center capacity constraints. A first-in-disease label can support premium pricing and create durable franchise value, but revenue recognition is likely uneven across the first 2-4 quarters; the market will discount headline TAM heavily until management provides treated-patient cadence, net price, and gross-to-net assumptions. The prior Angelman failure also means FAYUVI must carry a larger share of the company’s valuation narrative, increasing execution sensitivity.

Near term, approval should reduce regulatory risk and improve strategic optionality, including potential partnership or acquisition interest from rare-disease platforms such as SNY, TAK, or BMRN. Yet a single-dose AAV product has a finite prevalent-patient catch-up opportunity followed by a smaller incident population, so investors should avoid annualizing initial launch quarters. Manufacturing yield, durability evidence, and any safety signal in post-marketing surveillance are the principal 6-18 month determinants of whether the asset receives a platform-like multiple or remains a niche cash-consuming program.

The contrarian view is that sell-side target increases may be less informative than the reset in RARE’s cash runway after its pipeline setback. If FAYUVI uptake is slower than expected, additional financing or expense cuts could cap upside despite commercial success; conversely, early treatment-center activation and a credible reimbursement pathway could force a rapid reassessment because the stock’s current valuation appears to assign limited value to a successful launch. CF has no evident fundamental linkage to this development and should be excluded from the signal.

Key Decisions for Investors

• Initiate a small tactical long in RARE only after management discloses launch metrics or on confirmation that the stock holds above the post-approval reaction low; target a 20-30% rerating over 3-6 months if initial treated-patient and payer-access data exceed expectations, with a stop on evidence of delayed reimbursement or a material cash-runway deterioration.
• Prefer defined-risk exposure: buy 6-9 month RARE call spreads rather than outright shares before the first two commercial updates. The thesis requires observable uptake, while binary clinical, safety, and financing risks remain elevated; cap premium at approximately 1% of portfolio NAV.
• Set monitoring alerts for quarterly net product revenue, number of authorized treatment sites, treated patients, gross-to-net deductions, and updated cash guidance. Do not add exposure unless management can show a pathway to at least 18 months of liquidity without a dilutive raise.
• Avoid using CF as a sympathy or pair-trade leg; there is no credible operating, supply-chain, or valuation transmission mechanism from a rare-disease gene-therapy launch to nitrogen fertilizer economics.